Search Results - "Lachance, K."

High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma by Akaike, T., Qazi, J., Anderson, A., Behnia, F.S., Shinohara, M.M., Akaike, G., Hippe, D.S., Thomas, H., Takagishi, S.R., Lachance, K., Park, S.Y., Tarabadkar, E.S., Iyer, J.G., Blom, A., Parvathaneni, U., Vesselle, H., Nghiem, P., Bhatia, S.

“…Summary Background Merkel cell carcinoma (MCC) is an aggressive, high‐grade, cutaneous neuroendocrine tumour (NET). Agents blocking programmed death…”
Get full text

Health‐related quality of life in cutaneous T‐cell lymphoma: A cross‐sectional survey study by Shinohara, M.M., Mahurin, H.M., Tarabadkar, E., Hippe, D.S., Lachance, K., Kim, E.J., Loggers, E.T.

“…Summary Background Patients with cutaneous T‐cell lymphoma (CTCL) often have indolent but symptomatic disease. Objective Assessment of the health‐related…”
Get full text

Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma by Ramirez‐Fort, M. K., Meier‐Schiesser, B., Lachance, K., Mahase, S. S., Church, C. D., Niaz, M. J., Liu, H., Navarro, V., Nikolopoulou, A., Kazakov, D. V., Contassot, E., Nguyen, D. P., Sach, J., Hadravsky, L., Sheng, Y., Tagawa, S. T., Wu, X., Lange, C. S., French, L. E., Nghiem, P. T., Bander, N. H.

“…Backgrounds Folate Hydrolase‐1 (FOLH1; PSMA) is a type II transmembrane protein, luminally expressed by solid tumour neo‐vasculature. Monoclonal antibody…”
Get full text

Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients by Lachance, K, Korol, S, O'Meara, E, Ducharme, A, Racine, N, Liszkowski, M, Rouleau, J L, Pelletier, G B, Carrier, M, White, M, de Denus, S

“…It is not yet known whether healthy individuals and patients with a chronic disease have similar attitudes towards pharmacogenomics. Thus we conducted a survey…”
Get full text

Temporal Changes on the Risk of New Onset Diabetes Following Cardiac Transplantation Over 30 Years by Iannino, N, de Denus, S, Nasri, A, Räkel, A, Carrier, M, Ducharme, A, Lachance, K, Racine, N, Pelletier, G, Fortier, A, White, M

Get full text

TEMPORAL CHANGES ON THE RISK OF NEW ONSET DIABETES FOLLOWING CARDIAC TRANSPLANTATION OVER 30 YEARS by Iannino, N, de Denus, S, Nasri, A, Rakel, A, Carrier, M, Ducharme, A, Lachance, K, Racine, N, Pelletier, G.B, Fortier, A, White, M

Get full text

Risk Factors of Renal Dysfunction Following Cardiac Transplantation by Lachance, K, Carrier, M, Mansour, A, Ducharme, A, Racine, N, Liszkowski, M, White, M, de Denus, S

“…Purpose Post-transplant renal insufficiency is a growing problem. Our objective was to describe its incidence and risk factors in cardiac recipients. Methods…”
Get full text

664 Secular Trends of Renal Dysfunction and Its Risk Factors in Heart Transplantation by Lachance, K, Carrier, M, Ducharme, A, Racine, N, White, M, de Denus, S

Get full text

An exploratory study of factors affecting single trial P300 detection by Jansen, B.H., Allam, A., Kota, P., Lachance, K., Osho, A., Sundaresan, K.

“…A threshold detector for single-trial P300 detection has been evaluated. The detector operates on the 0-4 Hz band, isolated from the raw electroencephalogram…”
Get full text

493 Risk Factors for Renal Dysfunction Following Cardiac Transplantation by Lachance, K, Carrier, M, Mansour, A, Ducharme, A, Racine, N, Liszkowski, M, White, M, de Denus, S

Get full text

Horner Syndrome in Birds of Prey by LaChance, Mathieu K, Fitzgerald, Guy, Lair, Stéphane, Desmarchelier, Marion R

“…Horner syndrome, which results from oculosympathetic denervation, has rarely been reported in birds. A retrospective study was conducted in a raptor…”
Get full text

434 Novel management approaches for oligometastatic merkel cell carcinoma when standard systemic therapy is not an option by McClure, E., Akaike, T., Huynh, E.T., Harikrishnan, N., Lachance, K., Church, C., Pulliam, T., Nghiem, P.

Get full text

385 Complementary and alternative medicine (CAM) use in patients with cutaneous lymphoma by Mahurin, H.M., Tarabadkar, E., Hippe, D.S., Lachance, K., Shinohara, M.M.

Get full text

497 Efficacy of immunotherapy in Merkel cell carcinoma patients with chronic immunosuppression by Zawacki, L., Lachance, K., Akaike, T., Nghiem, P.

Get full text

826 Recurrence risk in seropositive merkel cell carcinoma: A web-based calculator to interpret merkel cell polyomavirus antibody test results by Gunnell, L.E., Lachance, K., Hippe, D., Bierma, M., Cahill, K., Akaike, T., Nghiem, P.

Get full text

247 Type of immunosuppression matters: Efficacy of immunotherapy in immunosuppressed Merkel cell carcinoma patients by Gong, E., Zawacki, L., Remington, A., Bierma, M., Lachance, K., Akaike, T., Nghiem, P.

Get full text

201 What is the risk of Merkel cell carcinoma recurrence beyond pathologically clear margins? An analysis of 926 cases by Fu, A., Singh, N., Lachance, K., Hippe, D., Nghiem, P., Park, S.Y.

Get full text

LB1690 Definitive radiotherapy for initial management of merkel cell carcinoma: Assessing a novel hypo-fractionated regimen by Menon, A., Huynh, E.T., Goff, P.H., Lachance, K., Nguyen, M.H., Iyer, J., Nagase, K., Parvathaneni, K., Nghiem, P., Parvathaneni, U.

Get full text

447 Immunotherapy efficacy in Merkel cell carcinoma is affected by the presence and type of immunosuppression: Analysis of 183 patients by Gong, E., Hippe, D.S., Fan, X., Zawacki, L., Remington, A.J., Menon, A., Lachance, K., Akaike, T., Park, S., Nghiem, P.

Get full text

562 Merkel polyomavirus antibody testing for detecting recurrent Merkel cell carcinoma: A prospective, real-world outcomes study by Gunnell, L., Akaike, T., Lachance, K., Hippe, D.S., Cahill, K., Doolittle-Amieva, C., Zawacki, L., Park, S., Nghiem, P.

Get full text